Sex disparity in acute myeloid leukemia – evidence from a study of *FLT3*-ITD mutated patients

Running title: Sex-disparity in *FLT3*-ITD mutated acute myeloid leukemia

Caroline Engen^{1*}, Monica Hellesøy^{2*}, Tim Grob³, Bob Löwenberg³, Peter J.M. Valk³, and Bjørn T. Gjertsen,^{1,2}

1 Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

2 Department of Internal Medicine, Haematology section, Haukeland University Hospital, Bergen, Norway.

3 Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.

*Authors contributed equally to this work

Correspondence: Professor Bjørn T. Gjertsen, Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Norway.

Tel.: +47 55 97 5000

Fax: +47 55 97 6752

E-mail: bjorn.gjertsen@uib.no

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Little attention has been directed at untangling sex-related molecular and phenotypic differences in AML. While increased incidence and poor risk is generally associated with a male phenotype, *FLT3*-ITD, *NPM1* and *DNMT3A* mutations are overrepresented in female AML. Here, we have investigated the relationship between sex and *FLT3*-ITD mutation status by comparing clinical data, mutational profiles, gene expression and *ex vivo* drug sensitivity responses in four cohorts: the Beat AML cohort, the LAML-TCGA cohort and two independent HOVON/SAKK clinical trial-associated cohorts, comprising a total of 1755 AML patients. We found that sex-associated molecular differences were prevalent in *FLT3*-ITD mutated AML. Co-occurrence of *FLT3*-ITD, *NPM1* and *DNMT3A* mutations was overrepresented in females, while males with *FLT3*-ITDs were characterised by additional mutations in genes involved in RNA splicing and epigenetic modification. Female and male *FLT3*-ITD mutated AML had diverging expression of multiple leukemia-associated genes, as well as discrepant *ex vivo* drug-responses, suggestive of discrete functional properties. Surprisingly, we found significant prognostication of *FLT3*-ITD only in female patients. Thus, we suggest optimisation of *FLT3*-ITD mutation status as a clinical tool in a sex-adjusted manner. We further hypothesize that prognostication, prediction and development of therapeutic strategies in AML can be improved by including sex-specific considerations.

Keywords: *FLT3*, *FLT3*-ITD, Sex, context-dependency

INTRODUCTION

Sex influences regulatory mechanisms of the haematopoietic system as well as innate and adaptive immune responses.^{1,2} Strong age- and sex-specific discrepancies in incidence of autoimmune conditions³ and cancer,⁴ including hematological malignancies,⁵ suggest fundamental genetic and endocrine sex-related variability.

Androgens have been used to treat various bone marrow (BM) failure syndromes since the 1960s,⁶ and the presence of hormone receptors on hematopoietic cells, including malignant cell populations, has been recognised for decades.⁷ Yet, little is known about the molecular mechanisms modulating hematopoiesis through sex hormone pathways, or their contribution in hematopoietic malignancies. It has been indicated that sex-hormone receptors significantly contribute in regulation of hematopoietic cell subsets, including stem and progenitor cells.⁸ Sex-disparity in acute myeloid leukemia (AML) incidence is known, with a progressive male excess with increasing age.⁹ It has also been shown that male AML patients have significantly inferior outcomes compared to females, both in adult and in pediatric AML.¹⁰ Sex-specific mutational profiles in AML have also been described; *FLT3*-ITD, *NPM1* and *DNMT3A* mutations are overrepresented in females,^{11,12} while mutations in *RUNX1*, *ASXL1*, *SRSF2*, *STAG2*, *BCOR*, *U2AF1* and *EZH2* are more prevalent in males.¹² Female overrepresentation among AML patients with co-occurrence of *DNMT3A*, *NPM1* and *FLT3*-ITD mutations has also been reported.¹³

Despite the demographic differences in survival and somatic mutation profiles, sex-specific considerations are currently not made in therapeutic assessment or clinical risk stratification. Amongst the mutations with reported sex-dependent discrepancies is internal tandem

duplications (ITD) of the FMS-like tyrosine kinase 3 (*FLT3*). *FLT3*-ITD is present in approximately 25% of AML cases, and is a negative prognostic marker that is integrated in standard risk stratification guidelines in AML as well as guiding *FLT3*-targeted therapy.^{11,14} Yet, the association between sex and *FLT3*-ITD mutations has not been explored in depth. Here, we present results from genomic, functional and time-to-event-analyses of four well-annotated cohorts, including the Beat AML cohort,¹⁵ the LAML-TCGA cohort¹⁶ and two independent HOVON/SAKK cohorts, in sum comprising 1755 AML patients. Cohort compositions with regards to sex and *FLT3* mutation status is described in Table 1, and comparative analyses of sex-differences related to clinical parameters are presented in Supplementary tables 1-3.

METHODS

Patient sample selection

We analysed four independent patient cohorts; The Beat AML, LAML-TCGA, HOVON 1 and HOVON 2 cohorts. Beat AML and LAML-TCGA cohorts were used for descriptive analyses of somatic variant profiles. The Beat AML cohort was further investigated by differential gene expression (DGE) analyses, and exploration of *ex vivo* drug response profiles. All four cohorts were included for time-to-event analyses. Data from Beat-AML¹⁵ and LAML-TCGA¹⁶ are publicly available. All patients in the two HOVON cohorts provided written informed consent at trial inclusion.

The Beat AML cohort comprises 672 specimens from 562 individuals. We restricted our analysis to samples the All.variants.csv file, downloaded from <http://www.vizome.org/aml/geneset/> on the 01.11.2018. This included 608 samples from 519 individuals. At inclusion, 15 individuals had two samples acquired from different tissues. The sample with the lowest number of recurrent mutations was discarded. We filtered the remaining

samples based on the variable “dxAtSpecimenAcquisition” and retained samples annotated as "Acute myeloid leukaemia (AML) and related precursor neoplasms", resulting in a total of 571 samples. For descriptive analysis of somatic variants, we included only the first sample when serial samples were present, resulting in 498 samples from 498 individuals. For DGE and drug response, we analysed 390 samples from 360 individuals and 359 samples from 322 individuals, respectively, including only samples with sample IDs overlapping with the exome sequencing data set (Supplementary figure 1A). For outcome assessment, we restricted the analysis to diagnostic samples, denoted "Initial Acute Leukemia Diagnosis", where survival data was present, resulting in 303 individuals (Supplementary figure 1B). Notably, we constructed an extended *FLT3*-ITD annotation based on the combination of the consensus *FLT3*-ITD variable from the clinical summary table (Table S5-Clinical Summary) and Pindel call of *FLT3*-ITDs, as reported in the All.variants.csv file.

The HOVON 1 and HOVON 2 cohorts comprise newly diagnosed AML patients aged 15-80 years treated on various study protocols of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the Leukemia Group of the Swiss Group for Clinical Cancer Research (SAKK) during the period 1987 to 2013. The sample selection analysed here was restricted to treatment-naïve non-APL AML patients with known *FLT3*-ITD status. This includes patients treated in the protocols HO04, HO04a,¹⁷ HO29,^{18,19} HO42,^{20,21} HO43²² and HO102.²³ The studies are previously published, and sampling and data acquisition were performed as previously described.^{24,25} Patients included in HO102 are referred to as HOVON 2, while the remaining patients comprise HOVON 1. Detailed information on the individual trials is available at <http://www.hovon.nl>.

LAML-TCGA is a strongly selected sample cohort, composed to cover the major cytomorphic and cytogenetic groups recognized in AML prior to 2013.¹⁶ The cohort comprises 200 de novo AML patients, including 92 females and 108 males ranging from 18-88 years. Due to its selective and unrepresentative composition, we have mainly used this cohort for integrated analyses. Single cohort comparative analyses of sex-differences related to clinical parameters were not performed. The TCGA-AML data analysis is based exclusively on variables as presented in the file “SuppTable01.xlsx”, downloaded from <https://gdc.cancer.gov/node/876>. For survival analysis, the variable “OS months 3.31.12” is used.

Statistics

For comparison of continuous variables, we applied the non-parametric Wilcoxon rank sum test/Mann-Whitney test. The Fisher exact test was applied for comparison of categorical data. For DGE analysis, we log-transformed the CPM matrix provided in “Table S9-Gene Counts CPM” by the formula: $CPM(\log_2 + 0.1)$. Analyses were performed in accordance with the Linear Models for Microarray Data pipeline in the Bioconductor R package (LIMMA version 3.38.3). For exploration of the drug sensitivity data from the Beat AML cohort, we analysed the area under the curve (AUC) values provided in “Table S10-Drug Responses”, applying categories from “Table S11-Drug Families”. Time-to-event analyses were performed by generation of Kaplan-Meier survival curves and compared for differences using the log rank test. For continuous variables, impact on outcome was evaluated by univariate cox models followed by multivariate logistic regression models. P-values were adjusted by the Benjamini-Hochberg method, and threshold was set at ≤ 0.05 . All statistical analyses were performed in R-Studio (version 1.1.453) and R (version 3.5.0). Graphs were made with ggplot2 (version 3.1.0) and figures made in Adobe illustrator CS6 (version 16.0.0).

RESULTS

Comparative genomic architecture

To provide a context for sex-related variant patterns, we compared the sex-related distribution of somatic variants annotated in the Beat AML cohort. We found that the number of somatic variants did not differ significantly across sexes, although male individuals tended to have higher numbers (Supplementary figure 2A). Comparing the number of highly recurrently mutated genes (mutated in >2% of the cohort), the same trend was apparent (Supplementary figure 2B). There were no sex-related differences within the *FLT3*-ITD mutated subgroup. We identified 28 highly recurrently mutant genes, of which 23 genes are autosomal and five are X-linked, including *BCOR*, *BCORL1*, *PHF6*, *STAG2*, and *ZRSR2*. The frequency of *FLT3* mutations and *DNMT3A* mutations were higher in females, although not statistically significant. However, seven other genes were significantly different; *NPM1* was overrepresented in females, while *RUNX1*, *ZRSR2*, *SRSF2*, *U2AF1*, *ASXL1* and *EZH2* were overrepresented in males (Figure 1). Notably, six of these seven genes are autosomal.

When expanding the selection to genes mutated in >1% of the total Beat AML selection, we found mutations in *ZNF711* exclusively in females, while *BRCC3* and *SMC3* were both significantly overrepresented in males (Supplementary figure 4 and supplementary table 4A). Within the *FLT3*-ITD positive group, we identified mutations in both *BCOR* and *CCND3* only in male *FLT3*-ITD AML (Supplementary table 4B). Interestingly, the *FLT3*-ITD negative male and female groups were significantly different: while *WT1* was significantly more frequent in females, *RUNX1*, *SRSF2*, *U2AF1*, *ZRSR2*, and *EZH2* were significantly characteristic of males (Supplementary table 4C). This pattern is largely attributable to the excess of male samples annotated as “transformed” (from a prior hematological malignancy). Excluding these cases, only the relationship between male sex and *SRSF2* and *U2AF1* remained significant. In

addition, *MXRA5* and *NF1* were identified as more frequently mutated in females, while *PHF6* was significantly overrepresented in males (Supplementary table 4D).

For comparison, the sex-related distribution of somatic variants in the LAML-TCGA cohort is presented in Supplementary table 5. Due to the selective composition of this cohort, integrated analyses were not performed.

We note that none of the significant sex-discrepancies observed in somatic mutations of single genes were statistically significant by adjusted p-value. However, many of our findings, including the association of *FLT3*-ITD, *NPM1* and *DNMT3A* mutations in females and *RUNX1*, *ASXL1*, *SRSF2*, *STAG2*, *U2AF1* and *EZH2* mutations in males, have previously been reported by others.¹¹⁻¹³ Thus, we report all findings significant by non-adjusted p value here.

The 28 recurrently mutated genes in the Beat AML cohort were subsequently categorised by gene product functional properties: DNA methylation, activating signalling, transcriptional regulation, tumour suppressor function, epigenetic modification, cohesion complex regulation, and RNA splicing. We found that 14% of female vs 31% of male individuals had at least one mutation in one of the four RNA splicing genes: *SRSF2*, *U2AF1*, *SF3B1* and *ZRSR2* (adj. p=0.0001). Similarly, 10% female vs 23% male individuals had at least one mutation in one of the four epigenetic modifier genes: *ASXL1*, *BCOR*, *EZH2* and *BCORL1* (adj. p=0.0004). The relationships remained significant in the non-transformed group for both RNA splicing genes (adj p=0.009) and for epigenetic modifier genes (adj. p=0.03). The association was also significant within the *FLT3*-ITD negative group, where both epigenetic modifier genes (p=0.01) and RNA splicing genes (p=0.001) remained significantly associated with males. In

the *FLT3*-ITD positive group, the same trend was apparent, although not significant by adjusted p-value (Supplementary table 6, Supplementary figure 5).

We further explored the distribution of mutations of the frequently *FLT3*-ITD co-mutated genes *DNMT3A* and *NPM1*. As this information was available for all four cohorts, integrated analysis was performed. Mutation status of all three genes was known in 1624 cases. We found that significantly more females than males had a mutation in at least one of these three genes. The combination *FLT3*-ITD and *NPM1* mutation without *DNMT3A* mutation, as well as the combination *FLT3*-ITD, *NPM1* and *DNMT3A* mutation were both significantly associated with females (Supplementary table 7, Supplementary figure 6).

We subsequently compared the distribution of variant allele frequencies (VAF) of the genes mutated at least 10 times in the Beat AML cohort, and found that VAF was significantly higher in male compared to female individuals in five genes. As expected, this included the X-linked genes *STAG2*, *PHF6* and *BCOR*, but also the autosomal gene *ASXL1*. *BCORL1*, despite being X-bound, did not have significantly higher VAF in males. *ZRSR2* was mutated exclusively in males (Supplementary figure 7).

FLT3 was not among the genes identified with significantly different VAF across the sexes. It has previously been shown that the allelic ratio (AR) of *FLT3*-ITD mutations has prognostic implications.^{26,27} To investigate whether there were sex-discrepancies in *FLT3*-ITD AR among these patients, we calculated the AR from the VAF (the approach is described in the figure legend of supplementary figure 8). We note that although there are no standardized approach to measure *FLT3*-ITD AR, it is commonly measured by DNA fragment analysis by capillary electrophoresis (CE).^{28,29} Here, we have used the VAF from next generation sequencing (NGS)

analyses to calculate AR, as it has previously been shown that there is high concordance between CE and NGS assays in measuring *FLT3* mutational burden in AML patients.³⁰ As was the case for VAF, we did not find significant differences in AR between males and females in this cohort (supplementary figure 8).

Gene Expression Analysis

Based on the sex-related pattern of *FLT3*-ITD and co-mutations, we questioned whether there were sex-disparity in gene expression in the *FLT3*-ITD mutated group. We analysed 380 specimens in the Beat AML cohort, comprising 163 female and 217 male samples, respectively, of which 51 female and 47 male *FLT3*-ITD positive samples (supplementary table 8). We identified a total of 39 differentially expressed genes; 16 upregulated and 23 downregulated in the female *FLT3*-ITD positive subgroup, including 14 Y-linked, 2 X-linked, 7 non-annotated and 16 autosomal genes (Supplementary table 9). Subtracting genes also differentially expressed in the *FLT3*-ITD negative group, we identified a total of 17 mRNA transcripts mapped to 16 genes, of which *GLI2*, *CCL1*, *JPH1*, *MDGA1*, *RASGRF1*, *AE000661.3*, *HOXB-AS3*, *IRX5*, *NETO1/RP11-713C5.1*, *UGT3A2*, *SIGLEC6*, and *MKRN3* were all significantly higher expressed in *FLT3*-ITD positive females, while *GPR126*, *SCRN1*, *HMGA2* and *FAT1* were significantly higher expressed in *FLT3*-ITD positive males (Figure 2A and B, Supplementary figure 9 and 10). Comparing *FLT3*-ITD positive (n=98) and negative specimens (n=282) irrespective of sex, we found that *GLI2*, *CCL1*, *JPH1*, *MDGA1*, *RASGRF1*, *AE000661.37*, *HOXB-AS3*, *IRX5*, and *RP11-713C5.1* were all significantly upregulated in *FLT3*-ITD positive AML, while *GPR126* was significantly downregulated.

To explore the functional relevance of genes identified as differentially expressed, we explored their inter-relationship with disease outcome in the 220 individuals in the Beat AML cohort where survival- and expression data was available. By univariate analysis, five of the 39

differentially expressed genes were identified as significantly correlated with outcome (Supplementary table 10): *NETO1*, *TMSB4Y*, *TTY10*, *HMGA2* and *FAT1*. In multivariate analysis including these five transcripts, only *NETO1* remained significant, while *HMGA2* and *FAT1* were borderline significant (Supplementary figure 11). High expression of these three genes significantly correlated to poor outcome (Figure 2C). Stratifying the patients by *FLT3*-ITD status, we found that high expression of *HMGA2* was significantly associated with poor prognosis in the *FLT3*-ITD negative sub-population only, whereas *FAT1* and *NETO1* remained significant in both *FLT3*-ITD positive and negative patients. Stratifying the patients by sex, high *FAT1* and *HMGA2* were significant negative prognostic markers in the male sub-population only, whereas high *NETO1* was significant in both sexes, although a stronger negative correlation was observed in the male sub-population (Supplementary figure 12).

Drug sensitivity and resistance testing

To further explore the functional consequences of the sex-discrepant leukemic architecture, we assessed the variation in drug sensitivity profiles in the Beat AML cohort (Supplementary table 11). We focused on the 113 compounds tested in a minimum of 100 specimens, and samples overlapping with our previous analyses, resulting in 348 specimens from 311 individuals. 96/113 compounds were annotated by mechanism of action and categorised into one or more of 39 different groups (Supplementary figure 13).

Comparing drug sensitivity across the 39 various groups between female and male individuals irrespective of ITD status, we identified a weak but significant relationship between RTK-RET inhibitors (1/39) and higher sensitivity in females. When comparing *FLT3*-ITD positive cases, six inhibitor families differed significantly: PI3K-AKT-MTOR, PI3K-MTOR, RTK-ERBB, RTK-INSR-IGF1R, SYK and CAMK inhibitors all demonstrated higher sensitivity in male

samples (Supplementary figure 14). Comparing female and male *FLT3*-ITD negative specimens, only MEK inhibitors was significantly different, and more potent in female samples.

When examining individual compounds, we identified five compounds with significantly sex-discrepant potency, irrespective of *FLT3*-ITD status: Females were more sensitive to AT7519, palbociclib, and quizartinib (AC220), while males were more sensitive to cediranib (AZD2171), and pazopanib (GW786034). Further, we identified three compounds that were significantly more potent in female *FLT3*-ITD negative samples, including AT7519, palbociclib, and trametinib (GSK1120212). Importantly, we identified 14 inhibitors that demonstrated significantly lower potency in female *FLT3*-ITD positive samples, with an overrepresentation of inhibitors targeting tyrosine kinase receptors and downstream targets known to be influenced by *FLT3*-ITD signalling, including idelalisib, BEZ235, MGCD-265, masitinib (AB 1010), NVP-ADW742, tivozanib (AV-951), S31-201, afatinib (BIBW-2992), PRT062607, PI-103, cediranib (AZD2171), lapatinib, STO609 and axitinib (AG-013736) (Figure 3A, Supplementary table 12, Supplementary figure 15).

To assess whether variation in gene-expression correlated with variation in drug-response, we further examined the pairwise relationships of the differentially expressed genes and the compounds with sex-discrepant potency in *FLT3*-ITD positive samples. We found that sensitivity to NVP-ADW742 correlated with increasing gene expression of 7/13 RNA transcripts identified as upregulated in female *FLT3*-ITD positive AML. Conversely, increasing *GLI2* expression correlated with reduced sensitivity to 4/14 drugs that were less potent in female *FLT3*-ITD positive AML (Figure 3B).

Survival

Finally, we investigated the relationships between sex and the prognostic strength of *FLT3*-ITD mutation status on all cohorts combined as well as separately (Supplementary tables 14 a-e). HOVON 1 (n=432) had a median follow up of 113.7 months while HOVON 2 (n =625) had a median follow up of 42.3 months. The Beat AML cohort had a short median follow up of 15.2 months. For survival analyses, only newly diagnosed cases were included (n=303). LAML-TCGA (n=200) had a median follow up 47.2 months.

Despite *FLT3*-ITD status being a recognised negative prognostic marker in AML, we found a significant correlation to poor outcome only in the HOVON 1 cohort (Figure 4B). When overall survival was analysed in the cohorts combined (n=1560), we found as expected that *FLT3*-ITD mutation status was associated with statistically lower survival (Figure 4A). However, when survival analysis for all cohorts combined was split by sex, the significant prognostic association of *FLT3*-ITD remained *only* in the female sub-population (Figure 4C). Analysing the cohorts independently, the same observation was apparent; *FLT3*-ITD was significantly correlated with poor outcome only in female patients in both the HOVON cohorts, and the same trend was observed in the Beat AML and LAML-TCGA cohorts, although not statistically significant (Figure 4D, Supplementary figure 16, Supplementary table 13 a-e).

DISCUSSION

In this work, we demonstrate sex-disparity in somatic variant composition, gene expression and *ex vivo* drug response patterns in *FLT3*-ITD mutated AML cases across four well-characterised AML cohorts. *FLT3*-ITD mutation status is integrated in standard risk stratification guidelines in AML. Yet, in the datasets we explored, *FLT3*-ITD mutation status separated the disease outcome only in female AML. This may indicate that the prognostic utility of *FLT3*-ITD

mutation status is different across sexes. One plausible explanation is related to discrepant distribution of age, disease presentation pattern and poor risk molecular features, most pronounced in the Beat AML cohort. Here, the mutated genes dominating the male *FLT3*-ITD negative subpopulation are associated with poor outcome and with MDS and secondary AML.³¹ Whether this relationship represents inclusion asymmetry or a natural distribution is unknown. A characterisation of the population-based Swedish Acute Leukemia Registry, however, suggested that AML with an antecedent haematological disease is more frequent in males.³² Similar to AML, there is female excess of MDS among younger individuals, and men with MDS have comparably inferior outcome.⁹ Additionally, mutations in several genes overrepresented in males in the Beat AML cohort, including *SRSF2* and *U2AF1*, are reportedly overrepresented in male MDS.³³

Another possible confounder is *FLT3*-ITD allelic ratio (AR). High AR has in several studies been linked to poor prognosis,^{26,27} and it has also been shown that AML patients with a high *FLT3*-ITD AR lacking *NPM1* mutations have a worse prognosis.³⁴ In the latter study, an excess of males was reported in this sub-group, although no significant sex-disparity was observed. In our analyses, we did not identify *FLT3*-ITD VAF nor AR as significantly different across sexes, suggesting that a difference in the mutational burden of *FLT3* is not the cause of the observed sex-discrepancy in the prognostic impact of *FLT3*-ITD.

The sex-specific age-distribution characterising AML demography suggest that cohort composition is an important confounder. The age-composition of the Beat AML cohort resembles the reported demographic distribution of AML far better than the strongly selected LAML-TCGA cohort, in part explaining the lack of sex-biased mutations in this cohort. One could argue that age-matching is the optimal condition for comparison. What remains, however,

is to identify the cell-intrinsic and cell-extrinsic mechanisms underlying the sex-disparity in AML incidence and molecular presentation. Mutations are stochastic events; thus there are no apparent reasons to suggest that male and female hematopoietic stem cells acquire discrete mutations. What is plausible, however, is that sex is an independent contextual contributor in determining the translational effect in comparative fitness of novel gene variants.

Interestingly, one of the very first papers characterising the FLT3 receptor suggested FLT3 mediated regulatory function not only in the hematopoietic compartment but also in the gonads, placenta and brain;³⁵ tissues characterised by sexual dimorphism. This suggests that downstream effects of FLT3 signalling may be influenced by sex-variation. This hypothesis has been substantiated by studies demonstrating functional relevance of FLT3 expression in germinal tissue^{36,37} and by investigation of the oestrogen receptor in FLT3 positive haematopoietic cells, progenitor cells and mature cellular subsets like dendritic cells.^{8,38} Together, these observations suggest inter-regulatory pathways between sex-steroid receptors and FLT3.

The DGE analysis showed distinct expression of leukemogenesis-associated genes, suggesting functionally relevant cell-intrinsic sex-dependent differences. Of the genes more highly expressed in female *FLT3*-ITD positive AML, the hedgehog signalling mediator *GLI2* has been associated with *FLT3*-ITD positive leukemia,³⁹ while *HOXB-AS3* is reportedly upregulated in *NPM1* mutated AML, and has been implied to contribute in regulation of AML cell-cycle progression.⁴⁰ Of the genes more highly expressed in male *FLT3*-ITD positive AML, *FAT1* was shown to be somatically mutated in *FLT3*-ITD positive AML, and significantly in combination with *NPM1* and *DNMT3*. *FAT1* was further shown to exert tumour-suppressor activity specifically in *FLT3*-ITD positive AML,⁴¹ perhaps providing a partial explanation for the lack

of prognostic impact of *FLT3*-ITD in this subpopulation. The negative prognostic impact related to differentially expressed genes was stronger in genes specifically down-regulated in female *FLT3*-ITD positive AMLs, namely *HMGA2* and *FAT1*. This may suggest that the sex-related discrepancies of outcome in *FLT3*-ITD mutated AML could be influenced by discrete molecular mechanisms.

We hypothesize a significant contribution of sex-specific leukemia-host interactions related to *FLT3*-ITD mutations. *Ex vivo* drug screens have shown that *FLT3*-ITD dependency is contingent on availability of growth factors, and response to FLT3-targeting drugs is partly permissive of culture conditions.⁴² This is substantiated by observed sex-related *ex vivo* drug response patterns in the study of the Cancer Cell Line Encyclopedia.⁴³ An important confounder for *ex vivo* drug screens is incubation time, and conclusions regarding the translational value of these data should be drawn with caution. Nevertheless, the sum of the *ex vivo* drug response patterns and clinical outcome analysis suggest that response to therapeutic intervention in *FLT3*-ITD mutated AML may be influenced by sex. This is in line with the observations in the phase III trials RATIFY¹⁴ and QuANTUM-R⁴⁴ treating *FLT3* mutated AML with midostaurine and quizartinib, respectively, both reporting survival benefit in the male sub-population only. Sex-divergent responses have also been reported in tyrosine kinase inhibitor treatment with sunitinib.⁴⁵ These observations may be of great importance for the field of precision hemato-oncology, as novel targeted therapies may benefit female and male individuals differently. Although men and women in an unstratified AML population have similar prospects, this picture may be significantly different within discrete molecularly defined strata.

CONCLUSIONS

Assessment of mutation status is becoming an integrated part of the diagnostic characterization of adult AML patients. This information is subsequently incorporated into risk stratification models and clinical decision-making. *FLT3*-ITD mutation status is well-established as a biomarker in AML. However, important questions remain regarding its optimal application and utility. Our observations suggest that *FLT3*-ITD mutation status should be optimized as a clinical tool in a sex-adjusted manner. Furthermore, we suggest that sex-specific considerations should be included in clinical risk stratification and considered in pre-clinical and clinical experimental design and in biomarker analyses in AML. Sex should further represent an independent stratification factor when randomizing to clinical trials, and be systematically included when analyzing and reporting on clinical data in AML. We hypothesize that addressing sex-related regulation of molecularly defined subgroups of AML could advance pathophysiological understanding, perhaps ultimately revealing new therapeutic possibilities.

ACKNOWLEDGMENTS

We are grateful to all patients that have participated in the respective clinical trials, and all members and clinical investigators of the HOVON/SAKK collaboration, the Cancer Genome Atlas and in the preparation and publication of the Beat AML sample cohort.

AUTHORSHIP

The study was designed by CE and BTG. CE analysed, interpreted, prepared data for presentation and wrote the paper. MH and BTG interpreted data and wrote the paper. TG, BL and PJMV collected data from the HOVON cohorts, and contributed with data interpretation and with manuscript preparation.

CONFLICT OF INTEREST

The authors declare no relevant conflict of interest.

FIGURE LEGENDS

Figure 1

Sex-separated overview of genes mutated in more than 2% (≥ 10 patients) of the sub-sampled Beat-AML sample cohort (n=498), identified by analysing the final curated exome sequencing variant list downloaded at <http://www.vizome.org>. Of note, the result of the *FLT3* gene is separated by ITD and non-ITD *FLT3* mutations on separate rows. In all other analyses in this report, *FLT3*-ITD annotations includes additional samples where *FLT3*-ITDs were identified exclusively by conventional methods.

Figure 2

A. Pairwise comparison (Wilcoxon rank sum test/Mann-Whitney test) of the 17 transcripts identified as differentially expressed between female and male *FLT3*-ITD positive samples based on the results of the DGE analysis. Each dot represents an individual specimen and the box plot graphically present the median and the spread. The lower and upper hinges correspond the 25th and 75th percentiles, respectively, and the upper and lower whisker extends to the largest and smaller values (no further than 1.5 times the total inter quartile range from the hinges). Only *FLT3*-positive samples are presented. The same comparison for *FLT3*-ITD negative samples is available in supplementary figure 9. **B.** Heatmap depicting unsupervised clustering of CPM-log2 values of all transcripts significantly differentially expressed between female and male *FLT3*-ITD positive individuals. Clustering was done by columns and rows, and then manually faceted by *FLT3*-ITD status and sex. **C.** Kaplan-Meier curve comparing the

outcome of patients characterised by high and low mRNA expression of *NETO1*, *HMGA2* and *FAT1*, respectively.

Figure 3

A. Comparison of area under the curve (AUC) between *FLT3*-ITD mutated female and male specimens for the 14 compounds identified to demonstrate significant sex-related divergence. The same comparison for *FLT3*-ITD negative samples is available in supplementary figure 13. (Wilcoxon rank sum test/Mann-Whitney test: $p < 0.05$). Additional statistical results for all compounds included in the analysis as well as sample size for all compared groups are summarised in supplementary tables 12 and 13. **B.** Heatmap graphically presenting the pairwise correlation between the CPM-log2 values of the differentially expressed genes and the area under the curve distribution of compounds identified as differentially potent across female and male *FLT3*-ITD positive samples. The heat represents the correlation coefficient. Only statistically significant correlations are plotted.

Figure 4

A. Kaplan-Meier curve comparing the outcome of *FLT3*-ITD mutated and non-*FLT3*-ITD mutated patients across the four cohorts analysed together. **B.** Kaplan-Meier curve comparing the outcome of *FLT3*-ITD mutated and non *FLT3*-ITD mutated patients analysed individually by cohort. **C.** Kaplan-Meier curve comparing the outcome of *FLT3*-ITD mutated and non *FLT3*-ITD mutated patients analysed across the four cohorts but analysed individually for females and males. **D.** Kaplan-Meier curve comparing the outcome of *FLT3*-ITD mutated and non *FLT3*-ITD mutated patients analysed individually by cohort and individually for females and males.

REFERENCES

1. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626-38.
2. Ratajczak MZ. Why are hematopoietic stem cells so 'sexy'? on a search for developmental explanation. *Leukemia*. 2017;31(8):1671-7.
3. Whitacre CC. Sex differences in autoimmune disease. *Nat Immunol*. 2001;2(9):777-80.
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.
5. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood*. 2010;116(19):3724-34.
6. Calado RT, Cle DV. Treatment of inherited bone marrow failure syndromes beyond transplantation. *Hematology Am Soc Hematol Educ Program*. 2017;2017(1):96-101.
7. Larocca LM, Piantelli M, Leone G, et al. Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoids. *Br J Haematol*. 1990;75(4):489-95.
8. Abdelbaset-Ismail A, Suszynska M, Borkowska S, et al. Human haematopoietic stem/progenitor cells express several functional sex hormone receptors. *J Cell Mol Med*. 2016;20(1):134-46.
9. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. *Br J Haematol*. 2002;118(4):1071-7.
10. Hossain MJ, Xie L. Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data. *Cancer Epidemiol*. 2015;39(6):892-900.
11. Juliusson G, Jadersten M, Deneberg S, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. *Blood Adv*. 2020;4(6):1094-101.
12. Metzeler KH, Herold T, Rothenberg-Thurley M, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood*. 2016;128(5):686-98.
13. Loghavi S, Zuo Z, Ravandi F, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. *J Hematol Oncol*. 2014;7:74.
14. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. *N Engl J Med*. 2017;377(5):454-64.
15. Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. *Nature*. 2018;562(7728):526-31.
16. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med*. 2013;368(22):2059-74.
17. Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. *J Clin Oncol*. 1997;15(12):3496-506.
18. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. *N Engl J Med*. 2003;349(8):743-52.

19. Vellenga E, van Putten WL, Boogaerts MA, et al. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia? *Bone Marrow Transplant.* 1999;23(12):1279-82.
20. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. *N Engl J Med.* 2011;364(11):1027-36.
21. Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. *Blood.* 2012;119(23):5367-73.
22. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. *N Engl J Med.* 2009;361(13):1235-48.
23. Lowenberg B, Pabst T, Maertens J, et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. *Blood.* 2017;129(12):1636-45.
24. Valk PJ, Verhaak RG, Beijnen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med.* 2004;350(16):1617-28.
25. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. *Haematologica.* 2009;94(1):131-4.
26. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood.* 2010;115(3):453-74.
27. Schlenk RF, Kayser S, Bullinger L, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. *Blood.* 2014;124(23):3441-9.
28. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. *Leukemia.* 2019;33(2):299-312.
29. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? *Hematology Am Soc Hematol Educ Program.* 2013;2013:220-6.
30. Smith CC, Perl AE, Altman JK, et al. Comparative Assessment of FLT3 Variant Allele Frequency By Capillary Electrophoresis and Next-Generation Sequencing in FLT3mut+ patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Who Received Gilteritinib Therapy. *Blood.* 2017;130(Supplement 1):1411-.
31. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood.* 2015;125(9):1367-76.
32. Hulegardh E, Nilsson C, Lazarevic V, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. *Am J Hematol.* 2015;90(3):208-14.
33. Wang X, Song X, Yan X. Effect of RNA splicing machinery gene mutations on prognosis of patients with MDS: A meta-analysis. *Medicine (Baltimore).* 2019;98(21):e15743.
34. Sakaguchi M, Yamaguchi H, Najima Y, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. *Blood Adv.* 2018;2(20):2744-54.
35. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene.* 1991;6(9):1641-50.
36. Okamura Y, Myoumoto A, Manabe N, Tanaka N, Okamura H, Fukumoto M. Protein tyrosine kinase expression in the porcine ovary. *Mol Hum Reprod.* 2001;7(8):723-9.

37. Kwon WS, Kim YJ, Ryu DY, et al. Fms-like tyrosine kinase 3 is a key factor of male fertility. *Theriogenology*. 2018;126:145-52.
38. Laffont S, Seillet C, Guery JC. Estrogen Receptor-Dependent Regulation of Dendritic Cell Development and Function. *Front Immunol*. 2017;8:108.
39. Lim Y, Gondek L, Li L, et al. Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. *Sci Transl Med*. 2015;7(291):291ra96.
40. Papaioannou D, Petri A, Thruue CA, et al. HOXB-AS3 Regulates Cell Cycle Progression and Interacts with the Drosophila Splicing Human Behavior (DSHB) Complex in NPM1-Mutated Acute Myeloid Leukemia. *Blood*. 2016;128(22):1514.
41. Garg M, Nagata Y, Kanojia D, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. *Blood*. 2015;126(22):2491-501.
42. Karjalainen R, Pemovska T, Popa M, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. *Blood*. 2017;130(6):789-802.
43. Liu X, Yang J, Zhang Y, et al. A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia. *Sci Rep*. 2016;6:22811.
44. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(7):984-97.
45. Segarra I, Modamio P, Fernandez C, Marino EL. Sunitinib Possible Sex-Divergent Therapeutic Outcomes. *Clin Drug Investig*. 2016;36(10):791-9.

Table 1 - Composition of all cohorts in relation to sex, age and FLT3 status

			Beat AML	HOVON1	HOVON2	LAML-TCGA
Total	All	Number	496*	432	625	200
		Median age (range)	61 (2-87)	46 (15-77)	53 (18-65)	57 (18-88)
	Female	Number	222	215	273	92
		Median age (range)	57.5 (2-85)	46 (16-77)	53 (19-65)	57 (21-88)
	Male	Number	276	217	352	108
		Median age (range)	63 (5-87)	46 (15-75)	55 (18-65)	58 (18-83)
ITD+	All	Number	123	117	146	39
		Median age (range)	61 (10-85)	47 (18-77)	50 (18-65)	57 (22-83)
	Female	Number	62	67	74	18
		Median age (range)	60 (22-79)	45 (18-77)	53 (19-65)	58.5 (25-68)
	Male	Number	61	50	72	21
		Median age (range)	61 (10-85)	47.5 (19-71)	48.5 (18-65)	57 (22-83)
ITD-	All	Number	373	315	479	161
		Median age (range)	62 (2-87)	45 (15-75)	55 (18-65)	57 (18-88)
	Female	Number	160	148	199	74
		Median age (range)	55.5 (2-85)	46 (16-74)	52 (19-65)	57 (21-88)
	Male	Number	213	167	280	87
		Median age (range)	64 (5-87)	45 (15-75)	65 (18-65)	58 (18-81)

*The sample selection analysed from the Beat AML cohort comprises a total of 498 samples, but age for two of these samples is not annotated

FIGURE 1

FIGURE 2

A

FIGURE 4